Novartis's Secukinumab Phase III Trial Shows Sustained Remission Rate Twice That of Placebo
Novartis has announced new data from the Phase III REPLENISH trial evaluating Cosentyx (secukinumab)...
U.S. Actinium Company's ATNM-400 Achieves 94.29% Tumor Inhibition Rate in Prostate Cancer Model
The radioconjugate ATNM-400 demonstrated superior antitumor activity compared to existing PSMA-targe...
Ultragenyx to Participate in Goldman Sachs Global Healthcare Conference
On June 3, U.S. biopharmaceutical company Ultragenyx Pharmaceutical announced that its President and...
MEDIPOST's Knee Osteoarthritis Product Receives FDA Approval to Initiate Pivotal Phase 3 Study
MEDIPOST, a South Korean company, recently announced that its knee osteoarthritis treatment product ...
Brazil's Vesper Launches $15 Million Funding Round to Co-Develop AI Biotechnology
Brazilian biotech startup studio Vesper Biotechnologies, after receiving investment from the Lafer f...
Zhuhai Selected as National Tech Transformation Pilot City, to Receive 300 Million Yuan Support
The Ministry of Industry and Information Technology organized expert evaluations, and Zhuhai has bee...
US Capricor DMD Therapy Under FDA Review, August 2026
Capricor Therapeutics Inc. (CAPR:NASDAQ) reported its first-quarter 2026 financial results and discl...
US-based Made Scientific to Manufacture NOVAKnee Implants
US cell therapy contract development and manufacturing organization (CDMO) Made Scientific has been ...
Spanish Report: Vyjuvek Achieves 67.4% Healing Rate for Butterfly Skin Disease
The gene therapy Vyjuvek (beremagene geperpavec) has recently received a Therapeutic Positioning Rep...
U.S. Study: GLP-1 Drug Users See 35% Lower Breast Cancer Diagnosis Rate
An observational study led by Elizabeth McDonald, a professor of radiology at the Perelman School of...